Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism

Anna Jacobs, Rajesh Kabra, Pranab Das, Carrie S. Oliphant

Research output: Contribution to journalReview article

Abstract

Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available. Ongoing prescriber vigilance is recommended as additional information continues to emerge with this class of medications. The purpose of this paper is to provide an update on the use of the direct oral anticoagulant agents for the prevention and treatment of thromboembolism.

Original languageEnglish (US)
Pages (from-to)89-99
Number of pages11
JournalFuture Cardiology
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Thromboembolism
Anticoagulants
Atrial Fibrillation
Venous Thromboembolism
Publications
Therapeutics
Population
edoxaban
betrixaban

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. / Jacobs, Anna; Kabra, Rajesh; Das, Pranab; Oliphant, Carrie S.

In: Future Cardiology, Vol. 14, No. 1, 01.01.2018, p. 89-99.

Research output: Contribution to journalReview article

Jacobs, Anna ; Kabra, Rajesh ; Das, Pranab ; Oliphant, Carrie S. / Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. In: Future Cardiology. 2018 ; Vol. 14, No. 1. pp. 89-99.
@article{eef3a7f75310440ea05375ce96ce8596,
title = "Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism",
abstract = "Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available. Ongoing prescriber vigilance is recommended as additional information continues to emerge with this class of medications. The purpose of this paper is to provide an update on the use of the direct oral anticoagulant agents for the prevention and treatment of thromboembolism.",
author = "Anna Jacobs and Rajesh Kabra and Pranab Das and Oliphant, {Carrie S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2217/fca-2017-0045",
language = "English (US)",
volume = "14",
pages = "89--99",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism

AU - Jacobs, Anna

AU - Kabra, Rajesh

AU - Das, Pranab

AU - Oliphant, Carrie S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available. Ongoing prescriber vigilance is recommended as additional information continues to emerge with this class of medications. The purpose of this paper is to provide an update on the use of the direct oral anticoagulant agents for the prevention and treatment of thromboembolism.

AB - Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available. Ongoing prescriber vigilance is recommended as additional information continues to emerge with this class of medications. The purpose of this paper is to provide an update on the use of the direct oral anticoagulant agents for the prevention and treatment of thromboembolism.

UR - http://www.scopus.com/inward/record.url?scp=85038610924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038610924&partnerID=8YFLogxK

U2 - 10.2217/fca-2017-0045

DO - 10.2217/fca-2017-0045

M3 - Review article

C2 - 29226697

AN - SCOPUS:85038610924

VL - 14

SP - 89

EP - 99

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 1

ER -